-Managing Director, Prospect Venture Partners
-Co-founder Prospect Venture Partners II and III

Career Highlights:
Dr. Tananbaum received his undergraduate degree and BSEE from Yale University, his MBA from Harvard Business School and his MD from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology.

Dr. Tananbaum's career has been in the private sector where he has helped found and lead financings for numerous biotechnology, pharmaceutical and healthcare service companies, including Jazz Pharmaceuticals, PatientCare, Predicant, Comphealth, Nanosys, Vanda Pharmaceuticals and Vitae Pharmaceuticals. Prospect Venture Partners II and III are dedicated life science funds with over $1 billion in capital under management.

Previously, as a partner at Sierra Ventures, he led investments in numerous companies, and from 1991-1993, Dr. Tananbaum was a senior product manager at Merck & Company.

Dr. Tananbaum founded two successful biotechnology companies -- GelTex which he founded in 1991 while fininshing his MD degree and which was ultimately purchased by Genzyme for $1.6 billion; and Theravanace, founded in 1997, which just announced a landmark partnership with Glaxco.